# Nest.Bio Ventures Nest.Bio Ventures is a Private Equity based in Cambridge, United States. ## Overview - **Organization type:** Private Equity - **Headquarters:** Cambridge, United States - **Region:** North America - **Address:** Cambridge, MA, United States - **Founded:** 2018 - **Assets under management:** Undisclosed - **Website:** www.nest.bio - **LinkedIn:** https://www.linkedin.com/company/nestbio ## Regulatory record - **Reports private funds:** No ## About Weis and his partners — Cheryl Cui, Hingge Hsu, and Daphne Teo with venture partners Xi Chen, Steven Landau, and Jeffrey Lu — founded Nest.Bio in 2018. The firm operates from Cambridge, Massachusetts, the densest biotechnology cluster in the United States. Unlike most venture franchises that raise blind-pool funds and source deals through networks, Nest.Bio builds its pipeline by offering private wet-lab and office space to therapeutics startups, then selecting residents for direct investment. Nest.Bio targets therapeutics companies at seed, start-up, and expansion stages. It invests from a dedicated venture vehicle while Hatch.Bio Labs, its sister real-asset entity, leases shared and private labs in Kendall Square. The structure gives Nest.Bio early visibility into tenant progress — burn rates, hiring velocity, assay data — before making funding decisions. The resident and graduate community has grown past 50 companies and created more than 1,000 local jobs; alumni collectively hold over $7 billion in market capitalization. Nest.Bio does not publicly disclose assets under management or total capital deployed. Its website highlights a dual operating-company and investment-vehicle architecture, with Hatch.Bio Labs serving as the lab-operations entity under the same Partner group. The team lists four partners, three venture partners, and one advisor — a lean structure consistent with an operator-heavy model that sources investments through tenancy rather than traditional fund-raising roadshows. Daphne Teo also serves as CEO of NSG BioLabs, a Singapore-based co-working lab platform, hinting at a potential parallel model in Asia. Nest.Bio's structural differentiator is the fusion of a real-estate operating business with a venture portfolio: it collects lab rent while earning equity upside from the same tenants. That hybrid design gives it a proprietary sourcing lane that pure financial venture firms cannot replicate without building physical infrastructure, and it concentrates the partnership's time on companies they can observe day to day rather than on external deal origination. ## Sectors - Biotechnology - Life Sciences ## People - James Weis — Partner, CEO Nest.Bio Labs and Hatch.Bio Labs - Cheryl Cui — Partner - Hingge Hsu — Partner - Daphne Teo — Partner, CEO NSG BioLabs - Xi Chen — Venture Partner - Steven Landau — Venture Partner - Jeffrey Lu — Venture Partner - Tim Lu — Advisor ## Questions ### How does Nest.Bio Ventures source its investments? Nest.Bio Ventures generates proprietary deal flow through its own lab infrastructure. The firm operates Nest.Bio Labs and Hatch.Bio Labs in Kendall Square, Cambridge, where resident biotech companies lease shared or private wet-lab and office space. The proximity lets the investment team observe company progress directly and move early on equity positions in the most promising tenants. External startups are considered, but the resident-graduate funnel forms the core of its sourcing model. ### Does Nest.Bio Ventures make direct investments or commit to external funds? Nest.Bio Ventures makes direct equity investments in early-stage biotechnology and therapeutics companies. The firm’s public materials describe a model where it works alongside founders to develop, fund, and commercialize their technologies, with no mention of participating as a limited partner in third-party venture funds. The structure centers on direct, company-level exposure sourced predominantly from its resident-company pipeline. ### What investment stages does the firm target? Nest.Bio Ventures covers a broad range from seed and start-up through growth and late-stage venture, with a clear tilt toward the earliest stages. The firm’s resident companies span early-stage R&D through expansion-stage enterprises, and its own capital is deployed flexibly along that curve. The incubator environment naturally emphasizes formation-stage therapeutics companies, which can access both lab infrastructure and first institutional capital through the platform. ### What is the relationship between Nest.Bio Labs, Hatch.Bio Labs, and the venture arm? Nest.Bio Labs and its successor brand Hatch.Bio Labs provide shared and private wet-lab and office space to resident biotech startups. Nest.Bio Ventures is the affiliated investment entity that selects a subset of those startups for direct equity funding. James Weis is CEO of both the lab operations and the venture entity, and the websites are hosted on a single nest.bio domain, signaling integrated governance even as the lab and venture activities remain operationally distinct. ## Related profiles - [NestaVera](https://altss.com/profile/nestavera) - [Neste Oil Pension Fund](https://altss.com/profile/neste-oil-pension-fund) --- Last updated: 2026-08-11T02:43:31.692Z Canonical page: https://altss.com/profile/nest-bio-ventures Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology